NCT04093596 - Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) | Biotech Hunter

Enrollment

132

Participants

Timeline

Start Date

September 23, 2019

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

GENETIC

ALLO-715

ALLO-715 is an allogeneic CAR T cell therapy targeting BCMA

BIOLOGICAL

ALLO-647

ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen

DRUG

Fludarabine

Chemotherapy for lymphodepletion

DRUG

Cyclophosphamide

Chemotherapy for lymphodepletion

DRUG

Nirogacestat

a small molecule, selective, reversible, noncompetitive inhibitor of γsecretase (GSI) that increases BCMA target density on the surface of multiple myeloma cells.

Trial Locations (11)

10065

Memorial Sloan Kettering Cancer Center, New York

37203

Vanderbilt-Ingram Cancer Center, Nashville

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

53226

Medical College of Wisconsin, Milwaukee

55905

Mayo Clinic, Rochester

78229

Texas Transplant Institute, San Antonio

78704

St. David's South Austin Medical Center, Austin

80218

Sarah Cannon/Colorado Blood Cancer Institute, Denver

85234

Banner MD Anderson Cancer Center, Gilbert

91010

City of Hope, Duarte

94305

Stanford Cancer Institute, Palo Alto